1236861-63-4 Usage
Uses
Used in Medicinal Chemistry:
Tert-butyl 3-(quinolin-2-yl)azetidine-1-carboxylate is used as a building block for synthesizing biologically active molecules. Its unique structure and properties allow it to interact with biological targets, making it a promising candidate for the development of new drugs and pharmaceuticals.
Used in Drug Discovery and Development:
Tert-butyl 3-(quinolin-2-yl)azetidine-1-carboxylate is used as a precursor for various synthetic transformations. Its tert-butyl ester group provides stability and protection, enabling the compound to be further modified and optimized for specific therapeutic applications. This makes it an interesting target for researchers in the field of drug discovery and development.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, tert-butyl 3-(quinolin-2-yl)azetidine-1-carboxylate is used as a key intermediate in the synthesis of various drug candidates. Its unique structure and properties contribute to the development of innovative and effective therapeutic agents, addressing unmet medical needs and improving patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1236861-63-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,6,8,6 and 1 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1236861-63:
(9*1)+(8*2)+(7*3)+(6*6)+(5*8)+(4*6)+(3*1)+(2*6)+(1*3)=164
164 % 10 = 4
So 1236861-63-4 is a valid CAS Registry Number.
1236861-63-4Relevant articles and documents
PDE 10a Inhibitors for the Treatment of Type II Diabetes
-
Paragraph 0607; 0615-0616, (2015/01/06)
Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
-
Page/Page column 87-88, (2011/12/02)
Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDEIO, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
AMINO-HETEROCYCLIC COMPOUNDS
-
Page/Page column 22, (2010/08/07)
The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
